Satralizumab might not be enough. Olamkicept (sgp130Fc) in Neuromyelitis Optica Spectrum Disorder

Satralizumab, the monoclonal antibody against IL-6R, has been approved not long ago in Neuromyelitis Optica Spectrum Disorder (NMOSD). Nonetheless, inhibiting IL-6 Receptor might not be enough, since Satralizumab results in inhibition of both pro and anti-inflammatory pathways of IL-6. The detrimental role of IL-6 in NMOSD could be mainly played by the trans-signaling. Olamkicept (sgp130Fc) is a recently approved monoclonal antibody that prevents only the trans-signaling pathway of IL-6 to be activated.